|
Pegfilgrastim (Neulasta) for stem cell mobilization Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Pegfilgrastim (Neulasta) for stem cell mobilization conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Pegfilgrastim (Neulasta) for stem cell mobilization Clinical research trials and Pegfilgrastim (Neulasta) for stem cell mobilization medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Pegfilgrastim (Neulasta) for stem cell mobilization. Pegfilgrastim (Neulasta) for stem cell mobilization Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Pegfilgrastim (Neulasta) for stem cell mobilization clinical trial. Subjects typically recieve the finest healthcare available for their Pegfilgrastim (Neulasta) for stem cell mobilization condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pegfilgrastim (Neulasta) for stem cell mobilization  Pegfilgrastim (Neulasta) for stem cell mobilization
Pegfilgrastim (Neulasta) for stem cell mobilization
For Condition: Multiple Myeloma
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: In recent years PBPC have replaced bone marrow as the source of hematopoietic stem cells for autologous transplantation. One of the cited advantages of this procedure is the avoidance of bone marrow harvest, which frequently requires general anesthesia. Other advantages include faster neutrophil and platelet engraftment times, faster immune recovery, decrease in the amount of tumor contamination and technical ability to obtain stem cells from patients previously considered unharvestable because of marrow fibrosis or because of prior radiotherapy to the pelvis. Filgrastim has emerged as the preferred cytokine for stem cell mobilization based on its safety profile and the positive experience in granulocyte donors however, the number of circulating CD34+ cells does not occur until the third day after starting filgrastim injections. Pegfilgrastim stimulates the production and maturation of neutrophil precursors and enhances the functions of mature neutrophils in the same manner as filgrastim. Data form normal volunteers and in studies of patients with cancer have shown prolonged serum levels of the cytokine, with "self-regulation" of pegfilgrastim levels as a function of the neutrophil count ). This confers a therapeutic advantage in clinical settings by allowing a less frequent dosing.
Details:
Eligibility:
Study Type: Interventional, Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/75 Years
Genders: Both
Protocol Entry Criteria: - Age 18 years or older. - Patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation and PBPC cell collection without chemopriming. - Zubrod performance status < 3 (Appendix E) - Serum bilirubin < 1.5 times the upper limit of normal. Serum SGOT and SGPT < 2 times the upper limit of normal. Serum creatinine < 2.0 mg/dl - WBC greater > 4,500/ul - Platelet count > 100,000/ul prior to first apheresis procedure - Patients should not have received prior chemotherapy. Only patients who have been treated with thalidomide+/- dexamethasone will be eligible. - Sufficient peripheral venous access or central venous catheter - Informed consent
Total Enrollment: 48
Location and Contact Information:
MD Anderson Cancer Center *Recruiting*
Houston, Texas, 770030
United States
Recruiting Chitra Hosing 713-745-5745
Additional Information:
Study ID Numbers: ID03-0164;
Study Start Date: December 2003
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00067639
Other Multiple Myeloma Studies:
1. Safety and efficacy of single-agent CC-5013 in subjects with relapsed and refractory multiple myeloma
2. Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
3. Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma
4. Chemotherapy Related Anemia
5. Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Related Studies:
Other Multiple Myeloma Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Pegfilgrastim (Neulasta) for stem cell mobilization
|
|
|
|
|
|
|
|
